CCS
NVO

Crosspoint Capital Strategies’s Novo Nordisk NVO Stock Holding History

Crosspoint Capital Strategies’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-9,958
Closed -$211K – 585
2015
Q4 		$211K Buy
+9,958
New +$276K 0.06% 222
2015
Q1 		– Sell
-420
Closed -$9K – 672
2014
Q4 		$9K Hold
420
– – ﹤0.01% 534
2014
Q3 		$10K Hold
420
– – 0.01% 374
2014
Q2 		$10K Sell
420
-1,780
-81% -$39.3K ﹤0.01% 403
2014
Q1 		$50K Buy
2,200
+100
+5% +$2.13K 0.02% 260
2013
Q4 		$10K Buy
+2,100
New +$36.6K ﹤0.01% 432

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Crosspoint Capital Strategies's NVO Position: Q1 2016 in Review

Crosspoint Capital Strategies sold out of Novo Nordisk (NVO) in Q1 2016, closing a stake of 9,958 shares — an estimated $211K sold.

Crosspoint Capital Strategies first reported a position in NVO in Q4 2013 and held it in 6 quarters. The position peaked at $211K in Q4 2015. 535 funds tracked by Wall St. Rank hold NVO as of Q1 2016.

  • Crosspoint Capital Strategies reported no remaining Novo Nordisk position as of Q1 2016 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 9,958 Novo Nordisk shares in Q1 2016, an estimated $211K.
  • Crosspoint Capital Strategies first reported a position in Novo Nordisk in Q4 2013 and held it in 6 quarters.
  • Crosspoint Capital Strategies's Novo Nordisk position peaked at $211K in Q4 2015.
  • 535 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2016.

Based on Crosspoint Capital Strategies's 13F filing for Q1 2016, filed 16 May 2016.